|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:antidote
|
gptkb:idarucizumab
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
B01AE07
|
|
gptkbp:bioavailability
|
6.5%
|
|
gptkbp:blackBoxWarning
|
increased risk of thrombotic events after premature discontinuation
risk of spinal/epidural hematoma
|
|
gptkbp:brand
|
gptkb:Pradaxa
|
|
gptkbp:CASNumber
|
211915-06-9
|
|
gptkbp:contraindication
|
active pathological bleeding
mechanical prosthetic heart valves
|
|
gptkbp:drugClass
|
gptkb:anticoagulant
antithrombotic agent
|
|
gptkbp:eliminatedIn
|
urine
|
|
gptkbp:eliminationHalfLife
|
12-17 hours
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:hasCYPInteraction
|
not a CYP substrate
|
|
gptkbp:hasInChIKey
|
QBPWTZUNXWNLGA-UHFFFAOYSA-N
|
|
gptkbp:hasMolecularFormula
|
C34H41N7O5
|
|
gptkbp:hasReversalAgent
|
gptkb:idarucizumab
|
|
gptkbp:hasSMILES
|
CC(C)N1C(=O)NC(C(=O)N(C2CC2)C3=CC=CC=C3)C1=O
|
|
gptkbp:hasUNII
|
2ZC1894524
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
DB09053
|
|
gptkbp:indication
|
treatment and prevention of deep vein thrombosis
treatment and prevention of pulmonary embolism
prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation
|
|
gptkbp:legalStatus
|
prescription only
patented
|
|
gptkbp:manufacturer
|
gptkb:Boehringer_Ingelheim
|
|
gptkbp:mechanismOfAction
|
direct thrombin inhibitor
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
627.74
|
|
gptkbp:name
|
gptkb:Dabigatran
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
35%
|
|
gptkbp:PubChem_CID
|
gptkb:DB09053
148124
D08167
CHEMBL1219
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
bleeding
gastrointestinal upset
|
|
gptkbp:synonym
|
gptkb:BIBR_1048
gptkb:Dabigatran_etexilate
|
|
gptkbp:target
|
gptkb:thrombin_(F2)
|
|
gptkbp:bfsParent
|
gptkb:ibrutinib
|
|
gptkbp:bfsLayer
|
7
|